The brand new combined group will be 1 of 2 businesses that constitute the new Agilent. The other is the chemical evaluation group, which will be led by Mike McMullen, who like Holmkvist is certainly a current group president and Agilent svp. The elected president of the older life sciences group, Nick Roelofs, ‘will keep Agilent to pursue other business opportunities,’ Agilent stated in a declaration that did not thank him for his program or make any more mention of Roelofs. ‘We are creating a new Agilent with a simplified structure that can move quickly to build up and deliver industry-leading total workflow solutions for our customers,’ Agilent president and CEO William Sullivan said.Martins, Ph.D., Neil Romberg, M.D., Hirsh Komarow, M.D., Ivona Aksentijevich, M.D., Hun Sik Kim, Ph.D., Jason Ho, Ph.D., Glenn Cruse, Ph.D., Mi-Yeon Jung, Ph.D., Alasdair M. Gilfillan, Ph.D., Dean D. Metcalfe, M.D., Celeste Nelson, C.R.N.P., Michelle O’Brien, B.S.N., Laura Wisch, M.S.N., Kelly Rock, M.D., Ph.D., Daniel C. Douek, M.D., Ph.D., Chhavi Gandhi, M.D., Alan A. Wanderer, M.D., Hane Lee, Ph.D., Stanley F. Nelson, M.D., Kevin V. Shianna, Ph.D., Elizabeth T. Cirulli, Ph.D., David B. Goldstein, Ph.D., Eric O. Long, Ph.D., Susan Moir, Ph.D., Eric Meffre, Ph.D., Steven M. Holland, M.D., Daniel L. Kastner, M.D., Ph.D., Matilda Katan, Ph.D., Hal M. Hoffman, M.D., and Joshua D. Milner, M.D.: Cold Urticaria, Immunodeficiency, and Autoimmunity Related to PLCG2 Deletions The genetic dissection of unique inflammatory phenotypes can identify and elucidate immunologic mechanisms and pathways.